Published in J Cell Biol on July 12, 1999
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med (2001) 3.62
Cellular strategies for controlling protein aggregation. Nat Rev Mol Cell Biol (2010) 3.54
Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol (2002) 2.76
PML nuclear bodies. Cold Spring Harb Perspect Biol (2010) 2.44
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
ICP0 induces the accumulation of colocalizing conjugated ubiquitin. J Virol (2000) 1.90
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Herpes simplex virus type 1 genomes are associated with ND10 nuclear substructures in quiescently infected human fibroblasts. J Virol (2007) 1.65
Proteasome-mediated degradation of the papillomavirus E2-TA protein is regulated by phosphorylation and can modulate viral genome copy number. J Virol (2000) 1.48
Herpes simplex virus type I disrupts the ATR-dependent DNA-damage response during lytic infection. J Cell Sci (2006) 1.43
Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. J Virol (2002) 1.42
DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol (2011) 1.42
Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action. Proc Natl Acad Sci U S A (2010) 1.25
Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine (2007) 1.21
Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Mol Cell Biol (2003) 1.21
Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. Proc Natl Acad Sci U S A (2001) 1.21
Infection of cells with human cytomegalovirus during S phase results in a blockade to immediate-early gene expression that can be overcome by inhibition of the proteasome. J Virol (2002) 1.19
PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation. Mol Cell Biol (2008) 1.17
Oligomerization of ICP4 and rearrangement of heat shock proteins may be important for herpes simplex virus type 1 prereplicative site formation. J Virol (2008) 1.10
Divergent N-terminal sequences target an inducible testis deubiquitinating enzyme to distinct subcellular structures. Mol Cell Biol (2000) 1.08
Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion. J Virol (2008) 1.07
Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology (2008) 1.05
RNA polymerase II inhibitors dissociate antigenic peptide generation from normal viral protein synthesis: a role for nuclear translation in defective ribosomal product synthesis? J Immunol (2010) 1.05
MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA. Proc Natl Acad Sci U S A (2012) 1.02
Analysis of A47, an immunoprevalent protein of vaccinia virus, leads to a reevaluation of the total antiviral CD8+ T cell response. J Virol (2010) 1.01
Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J Virol (2008) 1.01
Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters. Proc Natl Acad Sci U S A (2012) 1.01
Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J Virol (2006) 1.00
Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. J Cell Biol (2001) 1.00
Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem (2010) 1.00
Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling. Biochem J (2005) 0.95
Association of adenovirus with the microtubule organizing center. J Virol (2003) 0.95
Localization of proteasomes and proteasomal proteolysis in the mammalian interphase cell nucleus by systematic application of immunocytochemistry. Histochem Cell Biol (2007) 0.93
Nuclear polyglutamine-containing protein aggregates as active proteolytic centers. J Cell Biol (2008) 0.93
Subcellular recruitment of fibrillarin to nucleoplasmic proteasomes: implications for processing of a nucleolar autoantigen. Mol Biol Cell (2002) 0.92
The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0. J Virol (2003) 0.91
Protein quality control: the who's who, the where's and therapeutic escapes. Histochem Cell Biol (2007) 0.85
The potential link between PML NBs and ICP0 in regulating lytic and latent infection of HSV-1. Protein Cell (2012) 0.85
Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes. BMC Cell Biol (2009) 0.85
Identification and comparative analysis of hepatitis C virus-host cell protein interactions. Mol Biosyst (2013) 0.83
Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol (2003) 0.83
N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies. J Cell Sci (2010) 0.83
Identification of mammalian protein quality control factors by high-throughput cellular imaging. PLoS One (2012) 0.81
PA28αβ: the enigmatic magic ring of the proteasome? Biomolecules (2014) 0.81
p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes. Mol Cancer (2003) 0.80
Formation of Mallory body-like inclusions and cell death induced by deregulated expression of keratin 18. Mol Biol Cell (2002) 0.80
The export of major histocompatibility complex class I molecules from the endoplasmic reticulum of rat brown adipose cells is acutely stimulated by insulin. Mol Biol Cell (2001) 0.79
Ret Finger Protein: An E3 Ubiquitin Ligase Juxtaposed to the XY Body in Meiosis. Int J Cell Biol (2010) 0.78
Distant positioning of proteasomal proteolysis relative to actively transcribed genes. Nucleic Acids Res (2011) 0.78
MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2. J Virol (2014) 0.76
Ubiquitous Autofragmentation of Fluorescent Proteins Creates Abundant Defective Ribosomal Products (DRiPs) for Immunosurveillance. J Biol Chem (2015) 0.76
The benefits of local depletion: The centrosome as a scaffold for ubiquitin-proteasome-mediated degradation. Cell Cycle (2016) 0.75
Caveolin-1 is an aggresome-inducing protein. Sci Rep (2016) 0.75
Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands. J Immunol (2017) 0.75
The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components. Protein Sci (2008) 0.75
Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells. PLoS One (2013) 0.75
I've got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells. J Clin Invest (2016) 0.75
Insufficient Innate Immunity Contributes to the Susceptibility of the Castaneous Mouse to Orthopoxvirus Infection. J Virol (2017) 0.75
Microtubule regulation and function during virus infection. J Virol (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol (1985) 13.99
Aggresomes: a cellular response to misfolded proteins. J Cell Biol (1998) 11.24
Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol (1998) 7.27
SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell (1998) 6.62
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell (1994) 6.52
The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J (1998) 6.37
Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity (1997) 5.44
Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell (1994) 5.37
Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol (1998) 4.54
The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J Virol (1998) 4.43
Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet (1998) 4.27
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res (1996) 3.37
Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature (1998) 3.22
Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature (1997) 3.16
Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol (1999) 2.93
Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med (1988) 2.85
Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry (1997) 2.73
Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol (1996) 2.69
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54
The NPI-1/NPI-3 (karyopherin alpha) binding site on the influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol (1997) 2.51
Production and characterization of monoclonal antibodies specific to multi-ubiquitin chains of polyubiquitinated proteins. FEBS Lett (1994) 2.44
Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol (1998) 2.37
Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol (1981) 2.36
Dynamics of proteasome distribution in living cells. EMBO J (1997) 2.18
Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem (1997) 2.14
Preparation of nuclear matrices from cultured cells: subfractionation of nuclei in situ. J Cell Biol (1984) 2.07
PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood (1993) 1.82
SUMO-1: wrestling with a new ubiquitin-related modifier. Trends Biochem Sci (1997) 1.79
Nuclear dots: actors on many stages. Immunobiology (1997) 1.45
Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome. Eur J Cell Biol (1996) 1.42
Human proteasomes analysed with monoclonal antibodies. Biochem J (1995) 1.39
KEKE motifs. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors. FEBS Lett (1994) 1.37
Biology of simian virus 40 (SV40) transplantation antigen (TrAg). IX. Analysis of TrAg in mouse cells synthesizing truncated SV40 large T antigen. Virology (1983) 1.28
Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J Immunol (1998) 0.89
Proteasome inhibitors and antigen presentation. Biopolymers (1997) 0.86
The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell (1982) 12.44
A novel influenza A virus mitochondrial protein that induces cell death. Nat Med (2001) 9.90
Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol (1999) 7.18
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature (2000) 7.10
Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity (1997) 5.44
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
CD1 recognition by mouse NK1+ T lymphocytes. Science (1995) 5.33
Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum. J Cell Biol (1989) 4.81
The National Veterans Administration Surgical Risk Study: risk adjustment for the comparative assessment of the quality of surgical care. J Am Coll Surg (1995) 4.77
Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature (2001) 4.76
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature (1979) 3.91
Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol (1986) 3.72
Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature (1984) 3.21
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity (2000) 2.94
Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol (1996) 2.88
Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science (1989) 2.81
Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol (1992) 2.77
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol (2001) 2.77
Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science (1998) 2.76
Antigenic characterization of viruses by monoclonal antibodies. Annu Rev Microbiol (1981) 2.63
Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol (1973) 2.61
Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science (1988) 2.59
Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype. J Exp Med (1978) 2.54
Selection of influenza A virus adsorptive mutants by growth in the presence of a mixture of monoclonal antihemagglutinin antibodies. J Virol (1986) 2.52
The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol (1995) 2.48
Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology (1993) 2.40
CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38
Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol (1981) 2.36
Ubiquitination of HIV-1 and MuLV Gag. Virology (2000) 2.33
Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med (1992) 2.29
Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med (2001) 2.28
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine (1994) 2.22
The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor? J Virol (1996) 2.21
Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in redox potential. J Cell Biol (1998) 2.16
PB1-F2, an influenza A virus-encoded proapoptotic mitochondrial protein, creates variably sized pores in planar lipid membranes. J Virol (2004) 2.12
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol (1997) 2.12
Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol (1998) 2.03
The binary logic of antigen processing and presentation to T cells. Cell (1990) 2.03
TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. J Exp Med (1995) 1.96
Quantification of breast tissue index from MR data using fuzzy clustering. Conf Proc IEEE Eng Med Biol Soc (2004) 1.93
Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell (1992) 1.93
Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol (1994) 1.90
Recognition of cloned vesicular stomatitis virus internal and external gene products by cytotoxic T lymphocytes. J Exp Med (1986) 1.88
The interpretation of marker protein assays: a critical appraisal in clinical studies and a xenograft model. Br J Cancer Suppl (1980) 1.85
Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv Immunol (1999) 1.82
Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J (2000) 1.80
Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science (1990) 1.79
Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature (1973) 1.78
Naloxone hazard in infant of opioid abuser. Lancet (1989) 1.68
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr Top Microbiol Immunol (1990) 1.62
Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol (1986) 1.62
The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J (2000) 1.62
Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg (2001) 1.61
An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J (1997) 1.59
Monoclonal anti-hemagglutinin antibodies detect irreversible antigenic alterations that coincide with the acid activation of influenza virus A/PR/834-mediated hemolysis. J Virol (1983) 1.59
Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins. High frequency of nonresponder MHC class I alleles. J Exp Med (1988) 1.57
Postoperative and late survival outcomes after major amputation: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program. Surgery (2001) 1.56
Structure of the proteasome activator REGalpha (PA28alpha). Nature (1997) 1.56
Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J Exp Med (1991) 1.55
The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med (1997) 1.55